

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original): A crystalline donepezil hydrochloride form H1, characterized by an x-ray powder diffraction spectrum having peaks expressed as 2θ at about 15.2, 18.7, 20.6, 22.3, 23.5, 24.0, 24.6, 27.0, 29.0 and 30.5 degrees.
2. (Previously Presented): The crystalline donepezil hydrochloride form H1, further characterized by an x-ray powder diffraction spectrum as in FIG. 1.
3. (Previously Presented): A process for preparation of donepezil hydrochloride form H1 as defined in claim 1, which comprises the steps of: a) dissolving donepezil free base in ethylene dichloride; b) adding hydrochloric acid; and c) precipitating donepezil hydrochloride form H1 from the solution formed in (b) by adding an anti-solvent.
4. (Previously Presented): The process according to claim 3, wherein the anti-solvent is diisopropyl ether, n-hexane, n-heptane or diethyl ether.
5. (Previously Presented): The process according to claim 3, wherein the anti-solvent is diisopropyl ether.

6. (Previously Presented): A another process for preparation of donepezil hydrochloride form H1 as defined in claim 1, which comprises the steps of: a) dissolving donepezil hydrochloride in ethylene dichloride; and b) precipitating donepezil hydrochloride form H1 from the solution formed in (a) by adding an anti-solvent.

7. (Previously Presented): The process according to claim 6, wherein the anti-solvent is diisopropyl ether, n-hexane, n-heptane or diethyl ether.

8. (Previously Presented): The process according to claim 6, wherein the anti-solvent is diisopropyl ether.

9. (Original): A crystalline donepezil hydrochloride form H2, characterized by an x-ray powder diffraction spectrum having peaks expressed as 2θ at about 6.6, 6.8, 10.1, 12.8, 13.7, 15.0, 15.6, 16.5, 17.3, 18.4, 19.5, 19.8, 20.0, 21.6, 21.9, 22.3, 23.9, 24.2, 24.7, 25.3, 26.0, 26.9 and 28.2 degrees.

10. (Previously Presented): The crystalline donepezil hydrochloride form H2 as defined in claim 9, further characterized by an x-ray powder diffraction spectrum as in FIG. 2.

11. (Original): A process for preparation of donepezil hydrochloride form H2 as defined in claim

9, which comprises the steps of: a) dissolving donepezil free base in toluene; b) adding hydrochloric acid; and c) isolating donepezil hydrochloride form H2 by filtration or centrifugation.

12. (Canceled)

13. (Canceled)

14. (Currently Amended): A process for the preparation of donepezil hydrochloride monohydrate as defined in claim 12 characterized by an x-ray powder diffraction spectrum having peaks expressed as 2 θ at about 5.0, 10.0, 12.7, 13.2, 16.2, 20.0, 21.3, 23.1, 23.9 and 25.3 degrees, which comprises the steps of: a) dissolving donepezil free base in a mixture of chloroform and water; b) adding hydrochloric acid; and c) precipitating donepezil hydrochloride monohydrate from the solution formed in (b) by adding an anti-solvent.

15. (Previously Presented): The process according to claim 14, wherein the anti-solvent is diisopropyl ether, n-hexane, n-heptane or diethyl ether.

16. (Previously Presented): The process according to claim 14, wherein the anti-solvent is diisopropyl ether.

17. (Currently Amended): A ~~another~~ process for preparation of donepezil hydrochloride monohydrate as defined in claim 12 characterized by an x-ray powder diffraction spectrum having peaks expressed as 2θ at about 5.0, 10.0, 12.7, 13.2, 16.2, 20.0, 21.3, 23.1, 23.9 and 25.3 degrees, which comprises the steps of: a) dissolving donepezil hydrochloride in a mixture of chloroform and water; and b) precipitating donepezil hydrochloride monohydrate from the solution formed in (a) by adding an anti-solvent.
18. (Previously Presented): The process according to claim 17, wherein the anti-solvent is diisopropyl ether, n-hexane, n-heptane or diethyl ether.
19. (Previously Presented): The process according to claim 17, wherein the anti-solvent is diisopropyl ether.
20. (Original): A crystalline donepezil hydrochloride sesquihydrate, characterized by an x-ray powder diffraction spectrum having peaks expressed as 2θ at about 5.1, 10.8, 12.8, 13.3, 13.9, 15.0, 16.3, 17.1, 17.7, 19.5, 20.1, 21.4, 23.2, 24.1, 26.6, 27.3, 28.2, 29.7, 31.9 and 35.3 degrees.
21. (Previously Presented): The crystalline donepezil hydrochloride sesquihydrate as defined in claim 20, further characterized by an x-ray powder diffraction spectrum as in FIG. 4.
22. (Original): A process for preparation of donepezil hydrochloride sesquihydrate as defined in

claim 20, which comprises the steps of: a) dissolving donepezil free base in a mixture of tert-butyl alcohol and water; b) adding hydrochloric acid; and c) isolating donepezil hydrochloride sesquihydrate by filtration or centrifugation.

23. (Original): A pharmaceutical composition comprising donepezil hydrochloride form H1 of claim 1 and a pharmaceutically acceptable carrier or diluent.

24. (Previously Presented): The pharmaceutical composition comprising donepezil hydrochloride form H2 of claim 9 and a pharmaceutically acceptable carrier or diluent.

25. (Canceled)

26. (Previously Presented): The pharmaceutical composition comprising donepezil hydrochloride sesquihydrate of claim 20 and a pharmaceutically acceptable carrier or diluent.

27. (Previously Presented): The pharmaceutical composition of claim 23, wherein the said composition comprises donepezil hydrochloride sesquihydrate.